Home Science Kalshi and Polymarket bets on clinical trials criticized...
Science

Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'

Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
Key Points

Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.(Image credit: Fred Tanneau)

Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.

(Image credit: Fred Tanneau)

Kalshi (PERSON) Polymarket (PERSON) Fred Tanneau (PERSON)
Originally published by NPR Business Read original →